» Articles » PMID: 36802219

Short-chain Fatty Acids Improve Inflamm-aging and Acute Lung Injury in Old Mice

Abstract

A chronic proinflammatory milieu (inflamm-aging) is observed in the elderly and associated with poorer prognosis in acute lung injury (ALI). Gut microbiome-derived short-chain fatty acids (SCFAs) are known to have immunomodulatory capabilities, but their function in the gut-lung axis in aging is poorly understood. Here, we analyzed the gut microbiome and its impact on inflammatory signaling in the aging lung and tested the effects of SCFAs in young (3 mo) and old (18 mo) mice that received either drinking water with a mixture of each 50 mM acetate, butyrate, and propionate for 2 wk or water alone. ALI was induced by intranasal lipopolysaccharide (LPS; = 12/group) administration. Controls ( = 8/group) received saline. Fecal pellets were sampled for gut microbiome analysis before and after LPS/saline treatment. The left lung lobe was collected for stereology and right lung lobes for cytokine and gene expression analysis, inflammatory cell activation, and proteomics. Different gut microbial taxa, such as , , and correlated positively with pulmonary inflammation in aging, suggesting an impact on inflamm-aging in the gut-lung axis. The supplementation of SCFAs reduced inflamm-aging, oxidative stress, metabolic alteration, and enhanced activation of myeloid cells in the lungs of old mice. The enhanced inflammatory signaling in ALI of old mice was also reduced by SCFA treatment. In summary, the study provides new evidence that SCFAs play a beneficial role in the gut-lung axis of the aging organism by reducing pulmonary inflamm-aging and ameliorating enhanced severity of ALI in old mice.

Citing Articles

Therapeutic potential of short-chain fatty acids for acute lung injury: a systematic review and meta-analysis of preclinical animal studies.

Xie L, Wang L, Liao Y, Yao M, Mai T, Fan R Front Nutr. 2025; 11():1528200.

PMID: 39845918 PMC: 11752998. DOI: 10.3389/fnut.2024.1528200.


Indole-3-Aldehyde alleviates lung inflammation in COPD through activating Aryl Hydrocarbon Receptor to inhibit HDACs/NF-κB/NLRP3 signaling pathways.

Wang P, Tao W, Li Q, Ma W, Jia W, Kang Y J Mol Med (Berl). 2024; 103(2):157-174.

PMID: 39694936 PMC: 11799038. DOI: 10.1007/s00109-024-02506-9.


Gut microbial metabolism in Alzheimer's disease and related dementias.

Kang J, Vemuganti V, Kuehn J, Ulland T, Rey F, Bendlin B Neurotherapeutics. 2024; 21(6):e00470.

PMID: 39462700 PMC: 11585892. DOI: 10.1016/j.neurot.2024.e00470.


Probiotics, prebiotics, synbiotics and other microbiome-based innovative therapeutics to mitigate obesity and enhance longevity via the gut-brain axis.

Boyajian J, Islam P, Abosalha A, Schaly S, Thareja R, Kassab A Microbiome Res Rep. 2024; 3(3):29.

PMID: 39421246 PMC: 11480732. DOI: 10.20517/mrr.2024.05.


The emerging roles of microbiome and short-chain fatty acids in the pathogenesis of bronchopulmonary dysplasia.

Gao Y, Wang K, Lin Z, Cai S, Peng A, He L Front Cell Infect Microbiol. 2024; 14:1434687.

PMID: 39372498 PMC: 11449852. DOI: 10.3389/fcimb.2024.1434687.